Daré Bioscience (DARE) Set to Announce Quarterly Earnings on Monday

Daré Bioscience (NASDAQ:DARE) is set to issue its quarterly earnings data after the market closes on Monday, August 12th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Daré Bioscience (NASDAQ:DARE) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.12). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.52 million. During the same quarter in the previous year, the business earned ($1.08) earnings per share. On average, analysts expect Daré Bioscience to post $-3 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Daré Bioscience Stock Up 0.9 %

NASDAQ DARE traded up $0.03 on Tuesday, reaching $3.29. The company had a trading volume of 12,743 shares, compared to its average volume of 47,950. The stock has a market capitalization of $27.70 million, a PE ratio of -0.83 and a beta of 1.37. Daré Bioscience has a 12 month low of $3.05 and a 12 month high of $9.47. The firm’s 50 day moving average price is $4.31 and its 200 day moving average price is $4.68.

Analyst Upgrades and Downgrades

DARE has been the subject of several recent analyst reports. Brookline Capital Management raised shares of Daré Bioscience from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research note on Wednesday, May 15th. HC Wainwright reissued a “buy” rating and issued a $72.00 price objective on shares of Daré Bioscience in a research report on Wednesday, May 15th.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.